Rifabutin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Nontuberculous Mycobacterial Infections

Conditions

Nontuberculous Mycobacterial Infections

Trial Timeline

Jun 1, 1984 → May 18, 2017

NCT ID

NCT03164291

About Rifabutin

Rifabutin is a phase 3 stage product being developed by Pfizer for Nontuberculous Mycobacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03164291. Target conditions include Nontuberculous Mycobacterial Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00810446	Pre-clinical	Completed	Jun 1, 2009	Mar 1, 2018	Non-tuberculous Mycobacterial Diseases
NCT00810407	Pre-clinical	Completed	Nov 1, 2008	Jul 1, 2016	Tuberculosis
NCT03164291	Phase 3	Completed	Jun 1, 1984	May 18, 2017	Nontuberculous Mycobacterial Infections

Competing Products

8 competing products in Nontuberculous Mycobacterial Infections

See all competitors

Product	Company	Stage	Hype Score
ALIS + Azithromycin + Ethambutol + ELC	Insmed	Phase 3	74
ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)	Insmed	Phase 3	74
LAI plus multi-drug regimen	Insmed	Phase 2	49
Liposomal amikacin for inhalation (LAI) + placebo	Insmed	Phase 2	49
LAI (Liposomal Amikacin for Inhalation) 590 mg	Insmed	Phase 3	74
Molgramostim nebulizer solution	Savara	Phase 2	47
Inhaled molgramostim + Antimycobacterial regimen	Savara	Phase 2	47
Placebo + SPR720 500 mg + SPR720 1000 mg	Spero Therapeutics	Phase 2	44

Other Products from Pfizer